Drugs / Rivipansel
Trials 9
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT02998099 | Jan → Feb 2017 | — | GlycoMimetics Incorporated | Completed | No outcome recorded |
| Phase 1 | NCT02871570 | Sep 2016 → Feb 2017 | — | GlycoMimetics Incorporated | Completed | No outcome recorded |
| Phase 1 | NCT02813798 | Jun 2016 → Feb 2018 | impaired renal function disease | GlycoMimetics Incorporated | Completed | No outcome recorded |
| Phase 1 | NCT02217917 | Oct 2015 → Apr 2016 | — | GlycoMimetics Incorporated | Completed | No outcome recorded |
| Phase 1 | NCT01941511 | Aug 2013 → Aug 2014 | — | GlycoMimetics Incorporated | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00911495 | May 2009 → Jul 2010 | sickle cell disease | GlycoMimetics Incorporated | Completed | No outcome recorded |
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT01119833 | May 2010 → Dec 2012 | sickle cell disease | GlycoMimetics Incorporated | Completed | Missed primary |
| Phase 32 trials · 1 missed | ||||||
| Phase 3 | NCT02433158 | Dec 2015 → Nov 2019 | sickle cell disease | GlycoMimetics Incorporated | Terminated | No outcome recorded |
| Phase 3 | NCT02187003 | Jun 2015 → May 2019 | sickle cell disease | Biossil Inc. | Completed | Missed primary |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2019-08-02 | Pfizer | Results Pfizer Announces Phase 3 Top-Line Results for Rivipansel in Patients with Sickle Cell Disease Experiencing a Vaso-Occlusive Crisis pfizer.com ↗
Pfizer Inc. (NYSE:PFE) announced today that the Phase 3 R ivipansel (GMI-1070): E valuating S afety, E fficacy and T ime to Discharge (RESET) pivotal study did not meet its primary or key secondary efficacy endpoints. |
All press releases naming this drug 2 releases
Evidence & citations 11 cited values
Every value below carries the sentence it was read from. 12 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | rivipansel | “These results support a phase 3 study of GMI-1070 (now rivipansel) for SCD VOC.” PMID 25733584 ↗ Mar 2015 |
| Known as | GMI 1070 | “We performed a Phase 1 study of the selectin inhibitor GMI 1070 in patients with sickle cell anemia.” PMID 24988449 ↗ Jul 2014 |
| Known as | pf 06460031 | “A Phase 1, Randomized, Double Blind, Sponsor Open, Placebo Controlled, Single And Multiple Ascending Dose Study To Evaluate The Safety, Tolerability, And Pharmacokinetics Of...” NCT02217917 ↗ |
| Known as | PF-06460031-02 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3707446 ↗ |
| Known as | RIVIPANSEL SODIUM | ChEMBL registry synonym — accepted as the source's own label CHEMBL3707446 ↗ |
| Action | Inhibit | “This Phase 1/Phase 2 study will evaluate GMI-1070, a pan-selectin inhibitor” NCT00911495 ↗3“Leukocyte adhesion molecule-1 antagonist” CHEMBL3707446 ↗ “Selectin E antagonist” CHEMBL3707446 ↗ “P-selectin antagonist” CHEMBL3707446 ↗ |
| Modality | Small molecule | — CHEMBL3707446 ↗ |
| Route | Intravenous | “Intravenous GMI-1070 given as two doses over the course of one day” NCT00911495 ↗ |
| Target | SELE | “Selectin E antagonist” CHEMBL3707446 ↗ |
| Target | SELL | “Leukocyte adhesion molecule-1 antagonist” CHEMBL3707446 ↗ |
| Target | SELP | “P-selectin antagonist” CHEMBL3707446 ↗ |